Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 200 versus STALEVO 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 200 versus STALEVO 50.
STALEVO 200 vs STALEVO 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
STALEVO 200 contains carbidopa, levodopa, and entacapone. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain. Levodopa is decarboxylated to dopamine in the brain, restoring dopaminergic activity in the striatum. Entacapone inhibits catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa and prolonging its half-life.
Stalevo 50 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its central availability. Entacapone is a selective, reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa, thereby prolonging its half-life.
One tablet (levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg) administered orally 3 to 4 times daily, adjusted based on response and tolerability.
One tablet (carbidopa 12.5 mg, levodopa 50 mg, entacapone 200 mg) orally, up to 8 tablets per day in divided doses, adjusting based on individual response. Maximum levodopa dose: 800 mg/day.
None Documented
None Documented
Levodopa: 1.3 hours (with carbidopa). Entacapone: 0.4-0.7 hours. Carbidopa: 1-2 hours. Terminal half-life of levodopa is extended to ~1.5-2 hours in combination; clinical dosing is every 4-6 hours.
Levodopa: 1-3 hours (short half-life necessitates frequent dosing; COMT inhibition by entacapone prolongs elimination half-life by ~1-2 hours vs levodopa alone). Carbidopa: 1-2 hours. Entacapone: 0.4-0.7 hours (terminal half-life in plasma).
Carbidopa: 70% renal (unchanged and metabolites), 30% fecal. Levodopa: 70-80% renal (metabolites), <10% fecal. Entacapone: 90% fecal (unchanged and metabolites), 10% renal.
Renal: ~80% (carbidopa: 70% unchanged, levodopa metabolites: 70-80% as HVA/DOPAC); Fecal: ~20% (entacapone: primarily as glucuronide conjugates via bile).
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent